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Abstract
Introduction:Fibromyalgia (FM) is a chronic condition characterized by chronic pain, fatigue and loss of function which significantly
impairs quality of life. Although treatment of FM remains disputed, some studies point at the efficacy of interdisciplinary therapy. This
study aims to analyze the effectiveness, cost-utility and benefits of a multicomponent therapy on quality of life (main variable),
functional impact, mood and pain in people suffering from FM that attend primary care centers (PCCs) of the Catalan Institute of
Health (ICS).
Methods and analysis: A 2-phase, mixed methods study has been designed following Medical Research Council guidance.
Phase 1: Pragmatic randomized clinical trial with patients diagnosed with FM that attend one of the 11 PCCs of the ICS Gerència
Territorial Terres de l’Ebre. We estimate a total sample of 336 patients. The control group will receive usual clinical care, while the
multicomponent therapy group (MT group) will receive usual clinical care plus group therapy (consisting of health education, exercise
and cognitive-behavioural therapy) during 12 weeks in 2-hourly weekly sessions. Analysis: the standardized mean response and the
standardized effect size will be assessed at 3, 9, and 15 months after the beginning of the study using multiple linear regression
models. Utility measurements will be used for the economic analysis. Phase 2: Qualitative socio constructivist study to evaluate the
intervention according to the results obtained and the opinions and experiences of participants (patients and professionals). We will
use theoretical sampling, with 2 discussion groups of participants in the multicomponent therapy and 2 discussion groups of
professionals of different PCCs. A thematic content analysis will be carried out.
Ethics and dissemination: This study protocol has been approved by the Clinical Research Ethics Committee of the Fundació
Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (code P18/068). Articles will be published in
international, peer-reviewed scientific journals.
Trial registration: Clinical-Trials.gov: NCT04049006.
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1. Introduction
Fibromyalgia (FM) is a disease characterized by chronic pain,
fatigue, and loss of function, which physically limits the patient
and consequently impacts mood, the social and working
environments, generates sleep disturbances and generally impairs
quality of life.[1] FM is classified as a central sensitivity syndrome
(CSS), and is frequently associated to other CSS such as Chronic
Fatigue Syndrome and Multiple Chemical Sensitivity.[2,3]
The diagnosis of FM is based on clinical criteria, initially
defined by the American College of Rheumatology.[4,5] New
amendments added in 2016 improve the detection of the disease
in the primary care (PC) setting, although at the cost of lower
specificity.[6] Prevalence of FM in the general population ranges
between 0.2% and 6.6%, and in women from 2.4% to 6.8%.[7]
In Spain, prevalence is estimated at 2.45% (D. Seoane-Mato,
personal communication, July 2019), with a female/male ratio of
21:1, and is usually diagnosed in middle-aged people.[1,8]
The cost of FM for the health system is high.[9] Total annual
costs per patient in industrialized countries are estimated between
7256 and 7900 euros, and indirect costs (for instance,
productivity loss) are considered higher than direct costs (such
as medical visits and multiple prescriptions).[10–12] In addition,
when comparing with other conditions that cause chronic pain,
FM is associated with higher rates of unemployment and a higher
number of sick leave days.[13]
The best treatment for FM is currently disputed. Some studies
have shown clinical improvement with non-pharmacological
therapies, particularly with exercise[14] and with cognitive-
behavioral therapy (CBT).[15,16] There is also some evidence
on the effectiveness of multicomponent group therapy, which
involves patient education, exercise and CBT[17,18], with reported
clinical improvement that lasts 3 to 12 months after the
intervention.[19,20] Interdisciplinary interventions conducted
from hospitals[21–23] and PC[24–27] have obtained similar positive
results. The most recent review (2017) of the European League
Against Rheumatism (EULAR)[28] on the management of FM
endorsed the abovementioned therapies, and also included
promising results on complementary therapies such as mindful-
ness, hydrotherapy and acupuncture. There is also evidence on
the benefits of some drugs for the treatment of severe pain and
insomnia (amitriptyline and cyclobenzaprine, duloxetine and
pregabalin).[28]
Few studies on the economic evaluation of interventions for
patients with FM have been published to date.[29–33] With respect
to cost-utility, psychology-based therapies showed better results
in most studies.[30–33] A cost-utility study carried out in Spain that
compared a psychoeducational intervention with usual clinical
care found that on average, the incremental gain in quality-
adjusted life years (QALYs) per person was 0.12 (0.06 to
0.19).[30]
Complex interventions, as well as interventions based on
Health Coaching, aim to promote healthy habits. The design of
complex, multimodal, and interdisciplinary interventions aims to
achieve a better implementation of interventions adapted to the
people and their environment, and greater sustainability. The
Medical Research Council has established a methodology to
develop this type of interventions, which comprise various phases
that are implemented iteratively using both quantitative and
qualitative methodologies. The combination of methodologies
incorporates the input of patients, in order to better adapt the
intervention to their needs, and takes into account the character-
istics (social, resources, health etc.) of the environment where the
intervention takes place.[34–36]
In 2016, 18 accredited units specialized in Central Sensitivity
Syndromes (USCSS) were created throughout Catalonia,[37] with
the aim to provide consistent health care to all patients with
fibromyalgia.[38] The USCSS consist of interdisciplinary teams
based both in primary care centers (PCCs) and in hospitals.
After reviewing the available evidence, we want to propose a
therapy for patients with FM to be delivered within the primary
health care system. The objective of this proposal is to analyze the
effectiveness and cost-utility of a multicomponent therapy that
consists of health education, exercise and cognitive-behavioral
therapy, and to compare it with usual clinical care with regard to
quality of life, functional impact, mood and pain in patients with
FM that attend Primary Health Care Centers (PCCs) of the
Gerència Territorial Terres de L’Ebre of the Catalan Institute of
Health (ICS). Based on the data collected about the opinion and
experience of patients and professionals, the following aspects of
the implementation of the intervention will also be evaluated:
acceptability, adaptability, adherence, feasibility and compatibil-
ity. This intervention is founded on the transtheoretical model of
change, which can be applied to multiple behaviors and risk
factors and is recommended in research with amultibehavioral or
multiple risk approach. Furthermore, the intervention applies the
conceptual framework of the “5As” (Assess, Advise, Agree,
Assist, and Arrange-follow up) to standardize and facilitate the
intervention.[39,40]
2. Methods and design
2.1. Setting and participants
Participants will be patients diagnosed with FM that attend 11
PCCs of the ICS Gerència Territorial Terres de l’Ebre.
2.1.1. Inclusion criteria (all criteria must be met).
 Clinical diagnosis of FM (International Classification of
Diseases-10 codes: M79.0, M79.7);
 Having a phone number;
 Accepting participation in the study.
2.1.2. Exclusion criteria.
 Active psychotic episode;
 Intellectual impairment;
 Severe depression and personality disorder;
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 Auto/heteroaggressive behaviour;
 Self-reported use of psychoactive substances;
 Having previously participated in a multicomponent therapy
group (MT group) in the Terres de l’Ebre (pilot study);
 Unable to attend the group sessions.
2.2. Training of FM specialists
Before starting the study, a nurse or a general practitioner of each
PCC (hereafter called “FM specialists”) will receive training on
aspects related to FM, exercise, cognitive-behavioral therapy and
on themethodology of data collection for the study. To guarantee
quality and consistency, annual refresher training will be
provided.
Following Medical Research Council guidelines[35] on the
evaluation of complex interventions, we will conduct a mixed
methods study consisting of 2 phases. Figure 1 shows the study
flowchart.
2.3. Phase 1: Study of the effectiveness and cost-utility of
the intervention
2.3.1. Study design and sample size. We will carry out a
pragmatic randomized clinical trial (type: parallel group) with
patients suffering from FM to compare the effect of a
multicomponent therapy with usual clinical care in PC. The
intervention will be structured in study units. Each study unit
consists of a MT group and a control group, each with 10 to 12
participants. Assuming an alpha error of 0.05 and a beta error of
0.05 in a bilateral contrast, and an estimated dropout rate of 20%,
a sample size of 130 participants in each group of the study will be
required in order to detect a score difference equal or higher than 5
units in the Short Form 36 (SF-36) health survey questionnaire. A
common standard deviation of 10 is assumed. Based on these
calculations, we will create a total of 14 MT groups, with their
respective control groups, betweenApril andDecember 2019. The
number of participants estimated is 336 patients.
2.3.2. Randomization, recruitment, and data collection. For
each study unit a randomization list will be generated according
to Efron procedure,[41] using the IBM SPSS Statistics v.23.0.
package for Windows. An appointment will be arranged with
patients who meet inclusion criteria for the first interview, where
they will receive the information leaflet of the study and will sign
the informed consent form. Next, patients will be allocated to a
study group according to the randomization list. Additionally,
the patients will be asked to respond to the study questionnaires
(SF-36v2 health survey questionnaire[42] (Optum, Inc. license
number QM048943), Revised Fibromyalgia Impact Question-
naire (FIQR),[43,44] Visual Analog Scale (VAS),[45,46] tender
points[47] and Hospital Anxiety and Depression Scale
(HADS)[48,49]) and will take part in the activities planned for
each group (see below).
Control group: Patients in the control group will receive
regular clinical care in their PCC,[50] which consists on an
individual visit with the FM specialist, who will conduct a
standardized clinical history and will inform the patient on the
disease using a custom designed leaflet.
MT group: in addition to usual PC clinical care, participants
will receive MT consisting of health education, exercise and
cognitive-behavioural therapy, during 12 weeks in 2-hourly
weekly sessions (Fig. 2). Group therapy will be delivered by the
FM specialist in each PCC, with the support of the physiothera-
pist and the psychologist of the USCSS.
Patients in the control and MT groups will receive an
appointment to attend their PCC at 3, 9, and 15 months after
the beginning of the study. During these appointments they will
be asked to respond to the study questionnaires (SF-36, FIQR,
VAS, tender points and HADS).
All data will be collected in a software application that has
been custom designed for the treatment protocol of FM in the
study sites. This application will be available in the Terres de
l’Ebre ICS website and will be linked to the electronic medical
records. The application aims to standardize all information
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Figure 1. Flowdiagram of the study. FIQR=Revised Fibromyalgia Impact Questionnaire, HADS=Hospital Anxiety and Depression Scale, MT group=
multicomponent therapy group, SF-36=Short Form 36 health survey questionnaire, VAS=visual analog scale.
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related to patients with FM who visit the USCSS and will be used
for research and for clinical care.
2.3.3. Masking. Due to the study characteristics (pragmatic
trial), it is not possible to mask the health professionals and
participants. The data analyst will be blind to the patients’
allocation group.
2.3.4. Outcomes.Themain result variable of the study is quality
of life (SF-36v2).[42,51] Table 1 shows the study variables, the
measurement instruments and the timing of data collection. All
variables will be collected for both study groups. The cost-utility
variables will be collected at 2 time points: 1 year before the
beginning of the study and 1 year after the beginning of the study.
2.3.5. Statistical analysis. Data analysis will take place at
baseline and after 3, 9, and 15 months. Intention to treat analysis
will be used. The quality of data collection will be periodically
monitored to minimize biases due to incomplete data. The non-
response bias will be evaluated at all points of follow up.
Descriptive analyses of variables will be carried out using the
media (standard deviation), median (interquartile range) or
frequency (percentage), depending on the distribution of
variables.
For comparisons between and within the 2 study groups
(intervention and control) and the study variables, the following
tests will be used: Student’s t test for independent or paired data,
McNemar, Chi-square test and analysis of variance or the
corresponding non-parametric tests.
To evaluate the effectiveness of the intervention at each point
of follow up, we will calculate the change in scores of the SF-36
and the other questionnaires in the intervention group minus the
change in the control group, and the standardized effect size
(SES). The SES will be calculated as the difference of the mean of
the scores of both groups divided by the combined standard
deviation. To detect differences within each study group, the
difference of the means between baseline and each follow up
point will be calculated, and also the effect size or standardized
mean response (SMR), in accordance with Kazis’method.[52] The
SMR will be calculated as the mean change divided by the
standard deviation of change. To evaluate the SMR and the SES
we will use Cohen rule, which classifies effect size as small (0.2 to
0.5), medium (0.5 to 0.8), and large (greater than 0.8).
Finally, multiple linear regression models will be used to
explore the variables associated with the percentage change
[(follow-up scores minus baseline scores)/baseline scores  100]
of the scores in the SF-36 and other questionnaires. The
multivariate models will include variables that might be clinically
linked, and the variables statistically significant in the previous
bivariate analyses. Models will be also adjusted by confounding
variables. Interactions and collinearity will be evaluated.[53]
Statistical significance for all study tests will be set ata 0.05 and
95% CI. The statistical package IBM SPSS Statistics v.23.0.for
Windows will be used.
2.3.6. Economic evaluation. The perspective of the National
Health System will be used for the analysis of the economic
evaluation. The use of resources and their respective costs for
both groups will be described and compared. Temporal horizon
will be 12 months, with a discount rate of 3%. Costs will be
calculated according to the most recent official prices published in
the Diari Oficial de la Generalitat de Catalunya (DOGC)[54] for
the public sector, updated to 2019. The utilities will be calculated
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using the SF-36v2, to obtain the quality-adjusted life years
(QALYs) as effectiveness measure. The incremental ratio of the
cost-utility will be calculated dividing the difference in total mean
costs in both groups by the differences in QALYs. To check
robustness of results we will carry out a sensitivity analysis with
various discount rates and different costs. Table 1 shows costs-
related variables, measurement instruments and timing of data
collection.
2.4. Phase 2: Study of the evaluation of the intervention
using qualitative methodology
The evaluation of the intervention will be founded on the
constructs and guidelines suggested by experts of implementation
research.[55,56] The objective of this Phase is to evaluate the
intervention with the use of qualitative methodology, with the
aim to detect improvable aspects according to the opinion and
experiences of participants (users and professionals).
2.4.1. Study design. Interpretive, descriptive qualitative re-
search will be carried out.
2.4.2. Participants, sampling, and recruitment. Patients who
have participated in 95% of the MT group sessions, and PC
professionals. We will use theoretical sampling to achieve
maximum discursive variability. Informants of different gender,
age, socioeconomic status, geographical area and progression of
disease will be selected amongst participants. Regarding PC
professionals, we will include informants of both genders,
different age groups and disciplines (general practitioners, nurses,
psychologists, physiotherapists, rheumatologists and physical
medicine and rehabilitation doctors).
2.4.3. Data collection. Two discussion groups of participants
and 2 discussion groups of professionals from different PCCs will
be organized. These 4 groups of 8 to 12 people will follow a topic
list. When necessary, additional discussion groups will be
conducted to achieve discourse saturation. The discussion groups
will be audio and video recorded prior informed consent and will
be literally and systematically transcribed. Identifying data of the
informants in the transcripts will be anonymized.
2.4.4. Data analysis. The text corpus will include the transcripts
of the discussion groups and the field notes of the groups’
observers. After successive readings of the sole text corpus and
the formulation of pre analytical intuitions, a thematic interpre-
tive content analysis will be carried out with the support of the
Atlas-Ti programme and thereafter triangulated amongst the
various members of the research team.[57] The meanings will be
interpreted and an explanatory framework will be created with
the contributions of each type of informant (patients and
professionals participating in the study).
2.5. Ethics and dissemination
This study protocol (version 1, 04/04/2018) has been approved
by the Clinical Research Ethics Committee of the Fundació
Institut Universitari per a la recerca a l’Atenció Primària de Salut
Jordi Gol i Gurina (IDIAPJGol), on 25/04/2018 (code P18/068),
in agreement with the Declaration of Helsinki/Tokyo. All
participants will receive oral and written information about
the study and Informed Consent will be obtained. The research
team undertakes to invite patients in the control group to
participate in the next MT group that takes place in their PCC,
because this intervention is devised as a long-term healthcare
commitment. Confidentiality of study subjects will be guaran-
teed, in agreement with the Organic Law of Personal Data
Protection (03/2018 December 5, LOPD) and with the Regula-
tion (EU) 2016/679 (April 27) of the European Parliament and
Council of Data Protection (RGPD) and the national regulations
of application. Any alteration of the study protocol will be
submitted to the ethical committee of the IDIAPJGol for approval
and will be published in clinical trials.gov.
The results of the study will be published in scientific journals
and will be presented in national and international meetings. The
results will be communicated to the patients of our health region
by means of a meeting and also through the local and national
media, and will be also disseminated to the general population.
3. Discussion
This study aims to provide evidence on the effectiveness of a
multicomponent therapy implemented in the public primary care
setting with the objective to improve the quality of life of patients
diagnosed with FM.
The proposal of the study originates from a healthcare demand
which requires interdisciplinary collaboration between general
practitioners, nurses, psychologists, physiotherapists, rheuma-
tologists and physical medicine, and rehabilitation doctors. The
project will take into account the available health resources in PC,
the perceptions of patients and professionals, and will also
evaluate cost-utility.
Since current evidence suggests that multicomponent group
therapy is the most successful treatment for FM,[58–60] the
emerging challenge for the health system is to implement this
approach effectively and sustainably in PC. We believe that PC
constitutes the ideal setting for this type of interventions, since it
provides accessibility and long-term care. However, data from
the primary care setting and data comparing the cost-effective-
ness of treatments provided in PC versus hospital-based treat-
ments remain scarce.
If this intervention is effective, we anticipate a swift transfer of
results in our setting and in other regions of Spain with similar
primary care systems. A common strategic national health plan
would facilitate further expansion of this program. Moreover,
since other European nations have already implemented the
healthcare model organized in USCSS, they could also benefit
from our findings. A pilot study conducted in rehabilitation
centers in Belgian hospitals showed an improvement regarding
the impact of FM, pain in tender-points and other health
parameters at the end of a multicomponent therapy lasting 12
weeks that combined exercise and CBT, with the exception of
patients with moderate depression.[18] In this study improvement
started after 6 weeks of therapy, but no information is provided
on the duration of the beneficial effects.
One limitation of our project is that the group leaders cannot
be blinded to treatment allocation. However, the data analyst will
be blinded to the participants’ allocation group. In order to
minimize follow-up variability, the group leaders will receive
instruction before the start of the study, and subsequent annual
refresher training. In addition, the educational and therapeutic
contents of the group sessions will be standardized. Finally, all
study units will consist of the same 3 professionals: the FM
specialist of the PCC, a physiotherapist and one psychologist.
This study will provide novel scientific evidence, since few
randomized clinical trials in this area of knowledge include
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qualitative methodology to evaluate multicomponent interven-
tions.[58] The qualitative phase of the project will contribute data
for the evaluation of the acceptability and feasibility of the
intervention, in accordance with the opinion and experiences of
participants (patients with FM and health professionals). It will
also contribute information on barriers and facilitators that can
be used to design an intervention more flexible, dynamic, and
adapted to the needs of participants.
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